31,831 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Purchased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 31,831 shares of the company’s stock, valued at approximately $52,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its stake in Caribou Biosciences by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 42,653 shares of the company’s stock valued at $219,000 after purchasing an additional 3,594 shares in the last quarter. Green Alpha Advisors LLC increased its stake in Caribou Biosciences by 5.0% during the 1st quarter. Green Alpha Advisors LLC now owns 83,521 shares of the company’s stock valued at $429,000 after purchasing an additional 3,957 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Caribou Biosciences by 16.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,489 shares of the company’s stock valued at $60,000 after purchasing an additional 5,244 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Caribou Biosciences by 66.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,024 shares of the company’s stock valued at $88,000 after purchasing an additional 6,798 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Caribou Biosciences by 8.3% during the 1st quarter. Acadian Asset Management LLC now owns 156,238 shares of the company’s stock valued at $802,000 after purchasing an additional 11,921 shares in the last quarter. 77.51% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a report on Tuesday, September 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $14.00 price target on shares of Caribou Biosciences in a report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Caribou Biosciences Stock Up 4.5 %

Shares of NASDAQ CRBU opened at $1.87 on Friday. The company has a market cap of $168.89 million, a PE ratio of -1.29 and a beta of 2.27. The firm’s 50-day moving average price is $2.02 and its 200-day moving average price is $2.74. Caribou Biosciences, Inc. has a 52-week low of $1.50 and a 52-week high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Tuesday, August 6th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. Caribou Biosciences had a negative net margin of 372.78% and a negative return on equity of 34.76%. The business had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $3.31 million. As a group, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.76 EPS for the current fiscal year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.